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ABSTRACT
Tumor angiogenesis is essential for invasive tumor growth and metastasis. 
Dickkopf-1 (DKK-1), an antagonist of Wnt signaling, participates in tumor development 
and progression. We evaluated whether DKK-1 stimulation induces angiogenesis and 
the endothelial–mesenchymal transition (EnMT).
Human umbilical vein endothelial cells (HUVECs) were stimulated with recombinant 
DKK-1 (rDDK-1) or conditioned medium from a culture of DKK-1-transfected 293 cells. 
Following stimulation, the expression levels of angiogenesis-related factors and EnMT 
related markers were determined by immunoblot assays. In addition, the effects of 
exogenous DKK-1 on angiogenesis and EnMT were assessed by tube-formation, cell 
invasion, and wound-healing assays.
Human hepatoma cells, such as Hep3B and Huh-7, showed high levels of DKK-1  
expression, whereas 293 cells and HUVECs showed little or no DKK-1 expression. 
Increased endothelial cell tube formation and invasiveness were observed in HUVECs 
treated with concentrated conditioned medium from DKK-1-overexpressing 293 cells or 
rDKK-1. DKK-1-stimulated HUVECs also exhibited increased motility in wound-healing 
assays. Furthermore, the expression levels of angiogenesis-related factors, including 
vascular endothelial growth factor receptor 2 and vascular endothelial-cadherin, were 
increased in DKK-1-stimulated HUVECs. The expression of EnMT markers, such as 
vimentin and Twist, was also increased in DKK-1-stimulated HUVECs. However, no 
significant change in β-catenin or GSK3β expression was observed. 
Our in vitro data suggest that DKK-1 can enhance angiogenesis and EnMT by 
HUVECs independent of the Wnt signaling pathway. Modulation of DKK-1 expression may 
facilitate development of novel strategies to control tumor angiogenesis and metastasis.
INTRODUCTION
Dickkopf-1 (DKK-1) is a potent antagonist of Wnt/
β-catenin signaling [1]. DKK-1 acts as an inhibitory ligand 
of the low-density lipoprotein receptor-related protein 5/6 
co-receptors and subsequently blocks their interaction with 
Wnt, resulting in β-catenin degradation [2]. This inhibitory 
role of DKK-1 in Wnt/β-catenin signaling is supported by 
the downregulation of DKK-1 in human colon cancers 
and the correlation between high DKK-1 expression and 
favorable responses to chemotherapy in brain tumors [3]. 
In contrast, DKK-1 overexpression has been reported in 
various tumors, including human hepatoblastomas, Wilms’ 
tumors, multiple myelomas, and hormone-resistant breast 
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cancers [4–6]. In addition, DKK-1 is highly expressed in 
hepatocellular carcinoma (HCC) [7], which is significantly 
correlated with poorer pathologic grade and postoperative 
outcomes [8, 9].
To date, it has been demonstrated that DKK-1 
promotes angiogenesis during development, 
tumorigenesis, and inflammation [10]. DKK-1 enhances 
the angiogenic properties of human endothelial colony-
forming cells, and increases tumoral angiogenesis in 
breast cancer [11]. In osteoarthritic knee joints, DKK-1 
was associated with angiogenesis and cartilage matrix 
proteinase secretion [12]. In addition, Tung et al. reported 
that a DKK-1expressing HCC cell line showed an 
increased microvessel density around tumors [13], while 
another study showed that DKK-1–mediated endothelial 
cell activation led to increased vascular density and 
vessel diameter in rats [14]. These findings indicate that 
DKK-1 plays a role in microvascular remodeling and 
tumor angiogenesis activation, which may account for its 
promotion of cancer growth in vivo.
However, the mechanism underlying the role of 
DKK-1 in angiogenesis remains to be elucidated. In the 
present study, DKK-1 expression was determined in 
mouse HCC tissue and human HCC cell lines. In addition, 
the effects of DKK-1 on angiogenesis and endothelial–
mesenchymal transition (EnMT) were investigated. 
RESULTS
DKK-1 expression in HCC
DKK-1 expression was high in c-myc-overexpressing 
HCC mice tissue and in a Xenograft mouse model using the 
Hep3B cell line (Figures 1A and 1B) [15, 16], compared to 
the controls. In addition, DKK-1 was expressed in several 
human HCC cell lines. DKK-1 mRNA, DKK-1 protein, and 
secreted DKK-1 protein levels (Figure 1C–1E) were high in 
HepG2, Hep3B, and Huh7 cells but lower in SNU 449 and 
SNU 475 cells. In contrast, DKK-1 was not expressed in 
human umbilical vein endothelial cells (HUVECs) or 293 
cells (Supplementary Figure 1). All these support that DKK-
1 expression is related to HCC development.
DKK-1 increases motility, invasion, and tube 
formation
The effect on angiogenesis of DKK-1 stimulation 
was investigated. Concentrated conditioned medium 
of DKK-1-expressing 293 cells was first produced 
(Figure 2A). A high concentration of secreted DKK-1 
protein (pDKK-1) was confirmed by Western blot and 
ELISA (Figure 2A).
DKK-1 stimulation increased the motility, invasion, 
and tube formation of HUVECs compared to controls, 
suggesting increased angiogenetic potential (Figure 2B–2D). 
Treatment with recombinant DKK-1 (rDKK-1) resulted 
in concentration-dependent increases in motility, invasion, 
and tube formation by HUVECs (Supplementary Figure 2). 
In contrast, DKK-1 did not affect HUVEC proliferation, 
suggesting that cell proliferation did not influence the 
results of the motility, invasion, and tube formation assays 
(Supplementary Figure 3).
DKK-1 increases EnMT marker expression 
To investigate the influence of DKK-1 on EnMT, 
HUVECs were stimulated by DKK-1. DKK-1 stimulation 
led to increased N-cadherin, Twist and vimentin expression, 
and decreased vascular-endothelial (VE)-cadherin 
expression, compared to the controls (Figure 3A and 
3B). rDKK-1 exerted similar effects, in a concentration-
dependent manner (Supplementary Figure 4).
Effect of DKK-1 on gene expression profiles
DKK-1 stimulation using conditioned medium 
influenced the expression of genes related to angiogenesis 
and cell morphology (Figure 4A). A protein-protein 
interaction analysis indicated that the effect of DKK-1 
stimulation on the EnMT potential of HUVECs is related 
to changes in the expression of several genes, including 
vascular endothelial growth factor receptor 2 (VEGFR2) 
and N-cadherin (Figure 4B). In contrast, the expression 
of genes related to cell proliferation and stability was not 
influenced by DKK-1 stimulation. Treatment with rDKK-
1 yielded similar findings (Supplementary Figure 5). In 
addition to the high expression of VEGFR2 after DKK-1 
stimulation, it has been known that VEGFR2 can promote 
angiogenesis and blockage of VEGFR2 can prohibit cancer 
invasion. Accordingly, we focused on VEGFR2 in our 
following experiments.
DKK-1 induces angiogenesis via the VEGFR2 
signaling cascade
The role of the VEGFR2 signaling cascade in DKK-
1-induced angiogenesis was next evaluated. Simulation 
of HUVECs with DKK-1-conditioned medium resulted 
in increased expression of VEGFR2 compared to the 
controls (Figure 5A and 5B). Moreover, treatment with 
rDKK-1 induced increased expression of VEGFR2 in 
a concentration-dependent manner (Supplementary 
Figure 6). In addition, phosphorylation of VEGFR2 
downstream molecules (e.g., Akt and Erk) was increased 
by DKK-1 stimulation (Figure 5C). 
Because DKK-1 is an antagonist of the Wnt 
signaling pathway [10, 11], the expression of genes related 
to Wnt signaling in DKK-1-stimulated HUVECs was 
determined. No significant change in β-catenin or GSK3β 
expression was observed (Figure 5D). This suggests that 
the effect of DKK-1 stimulation on VEGFR2 expression 
is independent of the Wnt signaling pathway. 
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DISCUSSION
In this study, DKK-1 expression was high in HCC 
mice tissue and human HCC cell lines, in agreement 
with previous reports [9, 17], but it was not expressed 
in HUVECs. In addition, DKK-1 stimulation potentiated 
angiogenesis—as reflected by increased motility, 
invasion, and tube formation—by HUVEC cells. This 
was supported by increases in the expression of EnMT 
markers, such as N-cadherin, Twist and vimentin, and 
the decrease in VE-cadherin expression. The increased 
EnMT potential of DKK-1-stimulated HUVECs was 
found to be related to the activation of VEGFR2 and its 
downstream molecules, such as Akt and Erk. Finally, 
we found no significant change in β-catenin and GSK3β 
expression, indicating that DKK-1 stimulation influences 
angiogenesis by upregulating VEGFR2 expression 
(Figure 6).
A significant association between DKK-1 and 
angiogenesis has been reported previously. Tung et al. 
[13] observed that DKK-1-expressing tumors, established 
by injection of PLC/PRF/5 HCC cells into mice, showed 
an increased microvessel density score. Moreover, DKK-1 
mediates endothelial cell activation by suppressing 
the Wnt/β-catenin pathway [14]. In this study, using an 
in vivo microvascular remodeling animal model, DKK-1 
significantly increased vascular density and vessel 
diameter in rats. Similarly, Weng et al. [12] reported 
that DKK-1 promoted angiogenesis and cartilaginous 
degradation by synovial fibroblasts, accelerating synovial 
angiogenesis and cartilage destruction. Furthermore, 
DKK-1 treatment increased vessel formation in implanted 
Figure 1: Dickkopf-1 (DKK-1) expression in hepatocellular carcinoma (HCC). DKK-1 expression in c-myc-overexpressing 
HCC mice tissue (A) and xenograft mice using Hep3B cells (B). DKK-1 mRNA (C) protein (D) and secreted protein (E) levels were high 
in HepG2, Hep3B, and Huh7 cells, but lower in SNU 449 and SNU 475 cells.
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Matrigel plugs and xenografted tumors [11]. Taken 
together, the above findings suggest that DKK-1 plays a 
role in microvascular remodeling and tumor angiogenesis. 
However, conflicting results have also been 
reported. Inhibition of angiogenesis by DKK-1 was 
demonstrated due to its mitigation of ocular pathological 
neovascularization, characterized by excessive Wnt 
signaling [18]. Recently, it was reported that endothelial-
cell-specific overexpression of DKK-1 in mice results in 
important vessel defects, including reductions in radial 
vessel expansion and the number of tip cells and filopodia 
in the retina [19]. The reasons for these discrepancies 
regarding the influence of DKK-1 on angiogenesis are 
unclear. Although further investigations are warranted, 
differences in the DKK-1 dose, method of DKK-1 
manipulation, or functions of DKK-1 under various 
physiological conditions can be hypothesized.
Most cellular activities regulated by Wnt signaling 
are related to angiogenesis, particularly endothelial cell 
proliferation and morphogenesis. The role of Wnt in 
Figure 2: DKK-1 increases the motility, invasion, and tube formation of human umbilical vein endothelial cells 
(HUVECs). DKK-1 conditioned medium was manufactured by transfecting DKK-1 into 293 cells and confirmed by Western blot and 
ELISA (A). HUVECs cultured in DKK-1-conditioned medium exhibited increased motility (B), invasion (C), and tube formation (D) 
compared to the controls. NT, non-treated. 
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vascular development has been confirmed using targeted 
deletion mutants of Wnt signaling components in animal 
models [20, 21]. In addition, aberrant activation of Wnt 
signaling plays an important role in hepatocarcinogenesis. 
Consistently, inhibition of Wnt signaling exerted potent 
anti-HCC activity by increasing the rate of apoptosis of 
tumor cells and impairing tumor vascularization [22]. 
Given this role of Wnt signaling in vascular development, 
angiogenesis, and hepatocarcinogenesis, DKK-1 may 
be a good target for treating hypervascular tumors (such 
as HCC) by modulating angiogenesis. In contrast to 
low or no DKK-1 expression in normal cells or tissue 
as shown in this study, several HCC cell lines had high 
DKK-1 expression, and the serum level of DKK-1 in 
HCC patients is significantly associated with HCC 
staging, HCC recurrence after curative resection, and 
poor prognosis [9, 17]. These phenomena can indicate 
the DKK-1-mediated promotion of cancer growth by 
activation of tumor angiogenesis and support the rationale 
that DKK-1 can be a cancer-specific therapeutic target for 
HCC treatments. Indeed, sorafenib, the only approved 
molecular-targeted agent, which can suppress angiogenesis 
and tumor growth by inhibiting the Raf/MEK/ERK 
signaling pathway and receptor tyrosine kinases [23], 
prolongs the survival of patients with HCC. Interestingly, 
we found that the stimulation of HUVEC cells using the 
decreased concentration of DKK-1 in culture media by 
si-DKK1 treatment, led to the decreased expression of 
VEGFR2 (Supplementary Figure 7). This phenomenon 
can raise the necessities for further in-vivo studies which 
can provide the evidences that simultaneous suppression 
of VEGFR2 by blocking DKK-1 and sorafenib treatment 
can have synergistic effects on HCC treatment.
In our study, VEGFR2 expression was increased, 
and its downstream molecules—such as Akt and 
Erk—showed increased phosphorylation after DKK-1 
stimulation. VEGFR2 is a receptor tyrosine kinase expressed 
predominantly in endothelial cells [24]. Activation of 
VEGFR2 can initiate multiple signaling pathways that 
orchestrate a variety of complex biological effects, such as 
endothelial cell maturation, vessel lumen formation, vascular 
permeability, vasodilation, angiogenesis, and arteriogenesis 
[25]. Thus, it can be hypothesized that high DKK-1 
expression results in activation of VEGFR2 expression and 
increased sensitivity to VEGF in endothelial cells, which is 
significantly correlated with DKK-1 expression [26], during 
coordination of angiogenesis. The above results provide a 
rationale to support targeting of VEGFR2 using sorafenib, 
and show the potential of DKK-1 as a target of therapy 
[27]. Indeed, an anti-DKK-1 antibody suppressed HCC 
progression in a xenograft mouse model [13]. 
DKK-1 binds to the Wnt co-receptor LRP5/6, which 
inhibits the formation of a ternary receptor complex, 
resulting in blockade of β-catenin signaling [28]. In addition 
Figure 3: DKK-1 increases the expression of endothelial–mesenchymal transition (EnMT) markers in HUVECs. DKK-1 
stimulation resulted in increased N-cadherin, twist, and vimentin expression, and decreased VE-cadherin expression, compared to the 
controls by western blot (A) and mRNA level (B). NT, non-treated.
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to LRP5/6, DKK-1 also binds to Kremen (Krm)-1/2 with 
high affinity to inhibit Wnt/β-catenin signaling [2]. However, 
in our study, no significant changes in β-catenin and GSK3β, 
the components of Wnt signaling, were observed. Although 
we did not identify the receptor for DKK-1 that mediates its 
influence on angiogenesis, our finding suggests that DKK-1 
activates angiogenesis independently of the Wnt signaling 
pathway. A recent study reported that carbonic anhydrase IX 
(CA9), which modulates tumor-associated cell migration and 
invasion, interacts with DKK-1 [29]. Therefore, further work 
is required to identify the receptors or molecules associated 
with this role of DKK-1.
To date, the influence of DKK-1 on various cancer 
types has been controversial: DKK-1 was down-regulated 
Figure 4: Effect of DKK-1 on gene expression. DKK-1 stimulation influenced the expression of genes related to angiogenesis and 
cell morphology (A). A protein-protein interaction analysis indicated that VEGFR2 and N-cadherin are involved in the DKK1mediated 
enhancement of the EnMT potential of HUVECs (B).
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in colon cancer [30, 31], whereas its expression is high 
in hepatoblastomas, Wilms’ tumor, and multiple myeloma 
[32, 33]. Because we investigated the association between 
HCC and angiogenesis in this study, we could not 
provide evidences to explain the reason why DKK-1 acts 
differently in various cancer types. Although we believe 
that the tumor heterogeneity among different cancers, even 
in the same tumor [34, 35], and the different experimental 
designs with different experimental materials among the 
previous studies might be related to these discordant 
results in part, further well-designed studies are warranted 
to elucidate this issue.
In conclusion, although the mechanisms of action 
of secreted DKK-1, and its physiological relevance to 
angiogenesis, are not fully understood, our data show that 
DKK-1 can induce angiogenesis by regulating VEGFR2 
independent of the Wnt signaling pathway, and suggest 
that DKK-1 is a potential therapeutic target.
Figure 5: DKK-1 induces angiogenesis via the VEGFR2 signaling cascade. Treatment of HUVECs with DKK-1 conditioned 
medium resulted in increased expression of VEGFR2, and phosphorylation of downstream molecules such as Akt and Erk, compared to the 
controls (A–C). However, β-catenin and GSK3β expression was unaffected (D).
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MATERIALS AND METHODS 
Cell culture and transfection
Huh-7 (KCLB60104, Korean Cell Line Bank), 
Hep3B, HepG2 (KCLB88065, Korean Cell Line Bank), 
SNU449, and SNU475 cells were cultured at 37°C 
with 5% CO
2
 in Dulbecco’s modified Eagle’s medium 
(DMEM; Gibco, Grand Island, NY, USA), modified 
Eagle’s Medium (MEM; Gibco), or RPMI-1640 (Gibco) 
supplemented with 10% fetal bovine serum (FBS; 
Gibco). SNU449 and SNU475 cells were derived from 
a primary HCC taken from a Korean patient, The 293 
cells were cultured at 37°C with 5% CO
2
 in DMEM. 
HUVECs were cultured at 37°C with 5% CO
2
 in EGM-
2 Bullet Kit (Lonza, Walkersville, MD, USA). Cells 
were transfected with pcDNA3-DKK-1 (pDKK-1) using 
Fugene HD transfection agent (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions. 
After transfection, the cells were incubated for 6 h and 
transferred to fresh culture medium.
Cell growth assay
HCC cell growth rates were measured using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT; Amresco, Solon, OH, USA) method. First, cells were 
seeded in a 96-well plate at 5 × 103 cells/well and incubated 
at 37°C for 24 h in serum-free medium. Then, cells were 
transfected with pDKK-1 or rDKK-1as described above. After 
cultivation for 24 h, cells were transferred to culture medium 
containing 10% FBS. MTT was added to the wells, and the 
plates were incubated at 37°C for 3–4 hours to allow dye to 
penetrate the cells. The medium was removed and treated 
with dimethylsulfoxide (Sigma-Aldrich, St Louis, MO, USA) 
for 5 min at room temperature; its absorbance at 595 nm was 
analyzed using a spectrophotometer (Molecular Devices, 
Sunnyvale, CA, USA).
Figure 6: Conclusive figure summarizing the results.
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mRNA isolation and real-time RT-PCR 
RNA was extracted using a QIAGEN RNeasy 
mini kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions and reverse-transcribed (RT) 
using a Clontech RT Kit (Clontech, Mountain View, 
CA, USA). qPCR analysis was performed using SYBR 
Green Master Mix (Applied Biosystems, Foster City, CA, 
USA) and specific PCR primers (Supplementary Table 1). 
Amplification efficiencies were calculated for all primers 
using serial dilutions of pooled cDNA samples. The data 
were calculated, using the comparative (ΔΔCt) method, 
as the expression ratio to β-actin, the housekeeping gene. 
Data are shown as means ± standard error of the mean 
(SEM) of at least three independent experiments.
Immunoblot analysis
The proteins were separated according to 
their molecular weight via sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), 
transferred to a PVDF membrane (GE Healthcare, 
Amersham, UK), and probed with mouse monoclonal 
antibodies or rabbit polyclonal antibodies specific for 
the proteins of interest. The blots were developed using 
the enhanced chemiluminescence (ECL) technique 
(PerkinElmer, Boston, MA, USA) according to the 
manufacturer’s instructions, and the level of each protein 
was quantified and compared (DKK-1, VE-cadherin and 
Vimentin: Abcam, Cambridge, UK; VEGFR2, β-actin, 
AKT, pAkt, ERK, pERK, GSK3b and N-cadherin: Cell 
Signaling, Danvers, MA, USA; Twist: Millipore, Billerica 
CA, USA). To detect secreted DKK-1, an enzyme-
linked immunosorbent assay (ELISA; R&D Systems, 
Minneapolis, MN, USA) was performed according to the 
manufacturer’s instructions.   
Angiogenesis assay
HUVEC invasiveness was assessed in vitro using 
a transwell chamber (Corning Costar, Cambridge, MA, 
USA). Then, 3 × 104 HUVECS/well and treated rDKK-1 or 
conditioned medium of DKK-1–overexpressing 293 cells was 
transferred to each transwell chamber. Following incubation 
for 24 h, invading cells were stained with hematoxylin and 
eosin. The total number of invaded cells on the lower side of 
the filter was determined using a light microscope (Olympus 
America, Melville, NY, USA) at 40× magnification.
Tube formation by HUVECs was measured in 
Matrigel (BD Biosciences, San Jose, CA, USA). A 48-
well plate (BD Falcon, Bedford, MA, USA) was coated 
with 50 µl Matrigel (10 mg/mL) and plated with HUVECs 
(7 × 104/well); rDKK-1 or conditioned medium of 
DKK1overexpressing 293 cells was then added. The plates 
were incubated for 2.5 h, and tube formation was observed 
under a light microscope.
The migratory activity of DKK-1–stimulated 
HUVECs was assessed by migration assay. Cells were 
seeded at a density of 5 × 104 cells/well onto 12-well 
plates and incubated for 24 h. A linear wound was made 
by scratching the monolayer with a sterile (white) pipette 
tip. After washing, cells were treated with 1 mL serum-
free medium (control), rDKK-1 or conditioned medium 
of DKK-1–overexpressing 293 cells. Wound areas were 
photographed using an Olympus microscope (Olympus 
Optical Co., Tokyo, Japan).
mRNA sequencing and genome mapping of 
sequence reads 
Isolated total RNA was used to prepare an mRNA 
sequencing library using the Illumina TruSeq Stranded 
mRNA Sample Preparation kit (Illumina, San Diego, 
CA, USA) according to the manufacturer’s protocol to 
generate single 8 bp indices for multiplexing. Library 
quality and size were assessed using an Agilent 2100 
Bioanalyzer DNA kit (Agilent, Palo Alto, CA, USA). 
Potentially existing sequencing adapters and low-quality 
bases in the raw reads were trimmed using Cutadapt 
software. The cleaned high-quality reads were mapped to 
the human reference genome hg19 of the UCSC genome 
(https://genome.ucsc.edu) using TopHat2 software [36]. 
The sequencing libraries were prepared in a strand-
specific manner using the Illumina strand-specific library 
preparation kit during mapping. To quantify the mapped 
reads on the human reference genome in terms of gene 
expression values, Cufflinks software with the strand-
specific library option was used [37]. Gene annotation 
for the human reference genome hg19 in GTF format was 
used to quantify gene expression. Gene expression values 
were calculated in fragments per kilobase of transcript 
per million fragments mapped (FPKM). Differentially 
expressed genes between two biological conditions were 
analyzed using the Cuffdiff software in the Cufflinks 
package [37].
Statistical analysis 
Results were expressed as means ± SEM or 
frequencies (%). An independent t-test was performed 
to compare means between the control and experimental 
groups. All statistical analyses were performed using 
SPSS software (ver. 12.0; SPSS Inc., Chicago, IL, USA). 
A p-value of < 0.05 was considered to indicate statistical 
significance.
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